Neumora Therapeutics Antidepressant Stumbles in Clinical Trial

Watertown-based Neumora Therapeutics, a clinical-stage biopharm with a pipeline consisting of seven clinical and pre-clinical brain disease programs, has announced disappointing results from a Phase 3 study of navacaprant for the treatment of major depressive disorder (MDD). The study did not demonstrate a statistically significant improvement in MDD study participants overall.

“We are disappointed by the results…as they were not consistent with the body of evidence supporting this mechanism in MDD. There is a lot to investigate from this study, in particular the contrast in drug and placebo responses in…female participants compared to male participants,” said Rob Lenz, executive vice president and head of research and development at Neumora.

“Our strong financial foundation and cash balance of $342 million as of the end of the third quarter provides runway into mid-2026, and we look forward to providing additional updates on the navacaprant development program and our pipeline at the J.P. Morgan Healthcare Conference,” said Neumora President and CEO Henry Gosebruch, (Source: Neumora Therapeutics Website, 02 January, 2025)